Objective: This manuscript assesses association between depressive symptoms and symptoms from cancer and its treatment during the first 12 weeks of a new oral oncolytic treatment.
a clinical diagnosis of depression 3 but may increase clinic visits, extended hospitalizations, 4, 5 reduced adherence to treatment, [6] [7] [8] and lower quality-of-life. 6, [9] [10] [11] The relationship between depression and common symptoms/side effects has been studied. 12 Ciarmalle and Poli 13 and Uchitomi and colleagues 14 reported that somatic symptoms such as insomnia and fatigue may either cause depression or be a result of depression.
Conclusions from this work are plagued by the use of multiple assessments tools, differing thresholds for identifying depression, 15, 16 provider beliefs that feelings of depression are normal, and their reluctance to diagnose and treat depression. 17 Further, side effects from treatment and symptoms from other pathologies often overlap, 18 thereby clouding further the role of depression in symptom experience during cancer treatment.
This work extends this knowledge by determining the associations of depressive symptomatology with symptoms associated with oral oncolytic therapy within the first 12 weeks of initiation. Most studies indicate that patient depression is associated with higher levels of symptom severity, and some studies indicate that depression may intensify the cancer patient's perception of the symptoms. 19 However, We considered the distribution of the CES-D20 scores in the sample and used the cut-off of 8 or higher that corresponds with a T-score of 49.8; the PROMIS T-score of 50 is the mean for the United
States general population. 28 This score also corresponds to the mean in large general population samples that were used to validate the CES-D20. 23 This cut-off determines how persons above the national average for depressive symptoms may differ from those below this national standard with regard to each approach to cancer-related symptom severity. 
| Symptom experience
Eighteen cancer-and treatment-related symptoms were assessed, they are: anxiety; constipation; cough; diarrhea; fatigue; headaches; joint pain; lack of appetite; mouth sores; nausea or vomiting; numbness or tingling especially hands and feet; pain; redness or peeling in hands or feet; shortness of breath; skin rash; sleep disturbance; swelling of hands or feet; and weakness. At intake, 4, 8, and 12 weeks patients were asked if they had experienced each of these symptoms, those reporting "Yes" to each symptom were then asked to rate its severity on a 1 to 9 scale with 1 begin barely noticeable, to a 9 being worst possible. Severity was summarized as (1) summed index ranging from 0 to 162; and (2) number of symptoms scored at a 4 or higher (threshold) at each observation.
| Use of antidepressants
Antidepressant therapy was assessed via audit of each patient's medical record which took place at the end of the study. Each patient was then categorized according to whether or not they had been prescribed an anti-depressant medication at intake into the trial.
| Demographic data and clinical history
Data on age, sex, ethnicity, education, marital status, income, and employment status were obtained at baseline. Clinical data on cancer diagnosis, stage of cancer, medications for comorbidities, cancer treatments, and complications were obtained from the medical record audit conducted after patients completed the study (week 12) or dropped out. Oral oncolytic medications newly prescribed for patients were collapsed into four classes: kinase inhibitors, cytotoxics, sex hormone inhibitors, and others (Supplemental Table 1 ).
| DATA ANALYSES
Distributions of the symptom and CES-D20 scores were summarized.
Demographic and clinical characteristics of the sample were compared according to the baseline CES-D20 level using t-, chi-square, or Fisher's exact tests as appropriate. To assess the effects of depressive symptomatology of cancer-related symptoms, linear mixed effects (LME) model was fit for four repeated measures of symptom outcomes, summed severity index, and number of symptoms above threshold (one at a time). The explanatory variables were weeks 4, 8, and 12 (entered as a class variable to model potentially nonlinear patterns), trial arm, patient's age and sex, drug category, use of antidepressants, baseline CES-D20 score category (≤8 versus 8+), and baseline CES-D20 score by week interaction. The LME model generalizes classical analysis of repeated measures and allows for data missing at random, so that all patients with non-missing symptom and CES-D20 scores at baseline were analyzed. The inclusion of the CES-D20 level by time interaction was included to evaluate whether the relationship between depressive symptomatology and cancer-related symptoms changes as time progresses. Least-square means of symptom outcomes according to the levels of the interaction term were output from the LME models, and differences between them according to the levels of baseline CES-D20 were tested. The LME modeling was then repeated with time-varying CES-D20 as a covariate instead of fixed baseline CES-D20.
4 | RESULTS
| Description of sample
Of the 458 patients screened, 272 consented and completed baseline interviews. Two patients did not complete the CES-D20 at baseline and dropped out following baseline interview; thus, this manuscript is based on N = 270 patients. Table 1 provides a description of the primary study sample overall and according to CES-D20 level at baseline.
Patients were mainly Caucasian (89%), equal number of men and women, mean age was just over 60, and 74% had at least some college The strength of association between the CES-D20 at baseline and cancer-related symptoms differed over time; the interaction terms in the LME models were significant for both outcomes of symptom severity (F(3, 647) = 8.10, P < .01 for the interaction term) and number of symptoms above threshold (F(2, 647) = 6.04, P < .01). The LS means of cancer-related symptom outcomes according to the baseline CES-D20 level (Table 2 ) indicate while differences in cancer-related symptom experience according to the level of CES-D20 were significant at each time point, both mean difference in severity and number of symptoms above threshold decreased over time. While the mean levels of cancer-related symptom measures did not change over time among those with baseline CES-D20 ≤ 8, there was a significant decrease over time among those with baseline CES-D20 above 8
( Table 2 , Figure 1A ,C). When time-varying CES-D20 level was used as a covariate instead of the fixed baseline CES-D20, the findings were similar (Table 3 , Figure 1B Finally, age, sex, drug category, and use of anti-depressants were not predictive of cancer-related symptom experience in any of the models over and above the CES-D20 score.
| CONCLUSIONS
This investigation describes how levels of depressive symptomatology at the onset of oral oncolytic treatment and over 12 weeks differentiate patients according to cancer-related symptoms over time.
A recent review 1 indicates the prevalence of depressive disorders varies between 5% and 60% depending on diagnostic criteria, depressive assessment tools, and type and stage of cancer. The cut-off of 16
on CES-D20 has been used to screen for depression, 21, 23 and in past studies of this team with patients treated with infusion chemotherapy for solid tumor cancers, 34% of patients scored at or above 16. 29 In a recent study among patients hospitalized for advanced cancer, the rate of depressive symptoms was 29%. 30 In this sample of patients for whom oral oncolytic treatment often represented the last available line of treatment, only 23% scored at 16 or higher on the CES-D20. In this report, we used a lower cut-off of 8 on CES-D20 that corresponded to being above or below the national mean for depressive symptoms, according to the cross-walk between the CES-D20
and the PROMIS Depression measure. 28 Reasons should further examine multiple co-occurring symptoms during this treatment modality. Finally, these data were drawn from a symptom management trial that was successful in lowering symptoms at the 8-week observation compared with the control arm, with no significant differences at the 12-week observation. These observed differences, in part, were mitigated by the fact the arms of the trial were balanced according to level of depression at randomization, and trial arm assignment was controlled for in the present analysis.
| Study limitations

| Clinical implications
This work points to the potential value of a cut-off of 8 on the CES-D20
to differentiate the course of symptoms among cancer patients undergoing oral oncolytic treatments. These data could inform behavioral interventions for patients starting oral oncolytic treatment by first introducing strategies to treat and manage symptoms of depression and determining if subsequent self-management approaches toward other symptoms are more effective when depression is addressed.
Future work might compare strategies that combine management of depression with other symptoms, with those that focus on depression alone or other cancer-related symptoms alone. From such comparisons, more could be learned about how managing symptoms of depression may reduce the severity of other symptoms. 39 Further, these comparisons might indicate how soon and to what degree the severity of other symptoms may follow a reduction in depressive symptoms.
